ClinicalTrials.gg
CompletedNCT03046992Updated Mar 21, 2025

Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC

A Phase 1/2 interventional study of YH25448 in EGFR Gene Mutation, sponsored by Yuhan Corporation. Completed at 16 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-03-21.

Sponsored by Yuhan Corporation · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
224
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung — 6 open to participants now, 11 under way, 2 of them phase 3. lazertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
6th of 20
224 · median 67
Started
2017
the only one that year
Phase 1/2
2 of 20
none open now
Registered
1st of 20
by date
Lead sponsor
4 of 20
Yuhan Corporation

Among the 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung, this one is the 6th largest by enrollment, is the only one that started in 2017, is one of 2 in phase 1/2, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About lazertinib

lazertinib: first FDA approval 2024 (LAZCLUZE), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

YH25448 is an oral, highly potent, mutant-selective and irreversible EGFR Tyrosine-kinase inhibitors (TKIs) targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGFR. YH25448 is expected to beneficial for the NSCLC patients with brain metastasis due to good blood brain barrier (BBB) penetration property as well as for the treatment of primary lung lesion and extracranial lesions. This study will be conducted to evaluate the safety, tolerability and efficacy of YH25448 in locally advanced or metastatic NSCLC patients with EGFR mutations.

Read the detailed description

This is a first time in patient study primarily designed to evaluate the safety, tolerability, and efficacy of YH25448 in in patients with EGFR mutation positive (EGFRm+) advanced NSCLC with or without asymptomatic brain metastasis who progressed following prior therapy with an EGFR TKIs agent. This study is composed of 3 parts; part A is a dose escalation phase, part B is a dose expansion phase and part C is a dose extension phase.

In dose escalation phase, YH25448 will be escalated to reach either a maximum tolerated or absorbable dose in patients as defined by dose-limiting toxicity in NSCLC patients who progressed following prior EGFR TKIs treatment to evaluate the safety and tolerability. In dose expansion phase, further safety, tolerability, pharmacokinetic(PK) and efficacy will be evaluated at each dose level(s) of dose escalation phase in NSCLC patients who progressed following prior EGFR TKIs treatment and harbouring confirmed T790M mutation. In dose extension phase, additional 2 cohorts (2nd line therapy cohort, 1st line therapy cohort) will be enrolled to further assess the efficacy, safety, tolerability, and PK of YH25448 at the maximum tolerated dose (MTD) or recommended dose (RD) defined through dose escalation phase and dose expansion phase. Results of these studies will serve as the evidence for further clinical development.

This study will also characterize the metabolite(s) profile of YH25448 and determine PK of its metabolite(s) in biological samples if necessary. Also, exploratory correlation between biomarker profiles and pharmacokinetics/pharmacodynamics will be analyzed.

03

Conditions studied

  • EGFR Gene Mutation

Keywords

  • EGFR
  • Non-Small Cell Lung Cancer
  • T790M
  • Brain Metastasis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of NSCLC with single activating EGFR mutations.
  • (ECOG) performance status 0 to 1 with no deterioration over the previous 2 weeks and a minimum of 3 months.
  • At least one measurable extracranial lesion, not previously irradiated and not chosen during the study screening period.
  • Prior to enrolling in the study, patients must have central confirmation of T790M+ mutation status from a sample taken after documented progression on the EGFR-TKIs therapy according to cohort.

Exclusion criteria

Exclusion Criteria:

  • Spinal cord compression.
  • with symptomatic and/or requiring for at least 2 weeks prior to start of study treatment.
  • Known intracranial hemorrhage which is unrelated to tumor.
  • Central Nervous System (CNS) complications that require urgent neurosurgical intervention (e.g. resection or shunt placement).
  • prior to study treatment.
  • Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
  • Any cardiovascular disease as followed.

    • History of symptomatic congestive heart failure (CHF) or serious cardiac arrhythmia requiring treatment
    • History of myocardial infarction or unstable angina within 6 months of the first dose of study treatment
    • (LVEF) \< 50%
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
224 participants (actual)

Study arms

  • Experimental
    YH25448

    * Dose Escalation Phase: Consists of 7 Cohorts * Dose Expansion Phase: Consists of 5 Cohorts * Dose Extension Phase: Consists of 2 Cohorts

    Drug: YH25448

Interventions

  • * Dose Escalation: YH25448 20mg\~320mg, PO * Dose Expansion: YH25448 40mg\~240mg, PO * Dose Extension: Recommended Dose 240mg of YH25448

06

What researchers measure

Primary outcomes

  1. Safety and tolerability by Common Terminology Criteria for Adverse Events (CTCAE) v4.03

    To assess the safety and tolerability profile of YH25448 by Common Terminology Criteria for Adverse Events (CTCAE) v4.03; vital signs (blood pressure, pulse, weight); laboratory parameters (clinical chemistry, hematology, urinalysis); physical examination; centrally reviewed electrocardiograms (ECGs), echocardiogram or multiple gated acquisition scan and performance status.

    Time frame: Safety and tolerability profile will be collected from baseline until 28 days after the last dose, expected average 1 year.

  2. Objective Response Rate (ORR)

    Per Response Evaluation Criteria in Solid Tumours (RECIST version 1.1) assessed by MRI or CT. ORR is the percentage of patients with at least 1 visit response of Complete Response (CR) or Partial Response (PR) (according to independent review), prior to progression or further anti-cancer therapy.

    Time frame: At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.

Secondary outcomes

  1. Duration of Response (DoR)

    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT.

    Time frame: At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.

  2. Disease Control Rate (DCR)

    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT.

    Time frame: At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.

  3. Progression-Free Survival (PFS)

    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT. Kaplan-Meier plots will be used to summarize the progression-free survival.

    Time frame: At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.

  4. Overall Survival (OS)

    To obtain assessment of anti-tumor activity of YH25448 by evaluation of tumor response using RECIST version 1.1.

    Time frame: At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.

  5. Tumor shrinkage

    To obtain assessment of anti-tumor activity of YH25448 by evaluation of tumor response using RECIST version 1.1.

    Time frame: At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.

  6. Objective Intracranial Response Rate (OIRR)

    To obtain assessment of anti-tumor activity of YH25448 by evaluation of tumor response using RECIST version 1.1.

    Time frame: At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.

  7. Duration of Intracranial Response (DoIR)

    To obtain assessment of anti-tumor activity of YH25448 by evaluation of tumor response using RECIST version 1.1.

    Time frame: At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.

  8. Intracranial Progression Free Survival (IPFS).

    To obtain assessment of anti-tumor activity of YH25448 by evaluation of tumor response using RECIST version 1.1. Kaplan-Meier plots will be used to summarize the progression-free survival.

    Time frame: At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.

07

Study locations

16 sites
  • Chungbuk National University Hospital
    Cheongju-si, Chungcheongbuk-do 28644, Korea, Republic of
  • The Catholic University of Korea, Bucheon St. Mary's Hospital
    Bucheon-si, Gyeonggi-do 14647, Korea, Republic of
  • National Cancer Center
    Goyang-si, Gyeonggi-do 03080, Korea, Republic of
  • CHA Bundang Medical Center, CHA University
    Seongnam-si, Gyeonggi-do 13496, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, Korea, Republic of
  • The Catholic University of Korea, St. Vincent's Hospital
    Suwon-si, Gyeonggi-do 16247, Korea, Republic of
  • Gyeongsang National University Hospital
    Jinju-si, Gyeongsangnam-do 52727, Korea, Republic of
  • Inje University Haeundae Paik Hospital
    Busan, 48108, Korea, Republic of
  • Gachon University Gil Medical Center
    Incheon, 21565, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Kangbuk Samsung Hospital
    Seoul, 03181, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • SMG-SNU Boramae Medical Center
    Seoul, 07061, Korea, Republic of
  • Severance Hospital
    Seoul, Korea, Republic of
  • Ulsan University Hospital
    Ulsan, 44033, Korea, Republic of
08

References and documents

Publications

  • Kim B, Lee J, Jang H, Lee N, Mehta J, Jang SB. Effects of Acid-Reducing Agents on the Pharmacokinetics of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. Adv Ther. 2022 Oct;39(10):4757-4771. doi: 10.1007/s12325-022-02286-z. Epub 2022 Aug 13. PubMed 35962934 ↗
  • Cho BC, Han JY, Kim SW, Lee KH, Cho EK, Lee YG, Kim DW, Kim JH, Lee GW, Lee JS, Shim BY, Kim JS, Chun SH, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Lee Y, Lee DH, Kang JA, Lee N, Kwon MJ, Espenschied C, Yablonovitch A, Ahn MJ. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol. 2022 Apr;17(4):558-567. doi: 10.1016/j.jtho.2021.11.025. Epub 2021 Dec 24. Erratum In: J Thorac Oncol. 2024 Oct;19(10):1467. doi: 10.1016/j.jtho.2022.09.221. PubMed 34958928 ↗
  • Ahn MJ, Han JY, Lee KH, Kim SW, Kim DW, Lee YG, Cho EK, Kim JH, Lee GW, Lee JS, Min YJ, Kim JS, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Kim HT, Lee DH, Kim S, Cho BC. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. Lancet Oncol. 2019 Dec;20(12):1681-1690. doi: 10.1016/S1470-2045(19)30504-2. Epub 2019 Oct 3. PubMed 31587882 ↗
  • Yun J, Hong MH, Kim SY, Park CW, Kim S, Yun MR, Kang HN, Pyo KH, Lee SS, Koh JS, Song HJ, Kim DK, Lee YS, Oh SW, Choi S, Kim HR, Cho BC. YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 Apr 15;25(8):2575-2587. doi: 10.1158/1078-0432.CCR-18-2906. Epub 2019 Jan 22. PubMed 30670498 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Jan 2021, 46 months.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 46 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2017
First posted
Feb 8, 2017
StartActual
Feb 15, 2017
Primary completionActual
Jan 8, 2021
CompletionActual
Mar 30, 2023
Last update
Mar 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03046992
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
Feb 8, 2017
Start date
Feb 15, 2017
Primary completion
Jan 8, 2021
Completion
Mar 30, 2023
Last update
Mar 21, 2025

Study contacts

Yuhan Corporation
study director · Clinical Development Department

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lazertinib

Start the discussion